CHRM3 and non-small cell lung carcinoma: An in vitro study showed that M1 muscarinic receptor antagonist dicyclomine and/or M3 muscarinic receptor antagonis, derifenacine reduced viability and increased apoptosis of chemoresistant lines of non-small cell lung cancer (NSCLC) and prostate cancer (PCa) [172].